Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06743649 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1-PF-06743649 or placebo | EXPERIMENTAL | Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3 |
| Cohort 2-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 3-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 4-PF-06743649 or placebo | EXPERIMENTAL | - |
| Cohort 5-PF-06743649 or placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06743649 | DRUG | 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
| Placebo | DRUG | Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG...
PF-06743649 is an investigational small molecule being studied in healthy volunteers. It is being evaluated for safety, toleration, pharmacokinetics, and pharmacodynamics after multiple oral doses. The drug is in Phase 1 clinical development and is not approved for any indication.
PF-06743649 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company is conducting clinical research on this investigational small molecule in healthy participants.
PF-06743649 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational. It has not been approved by regulatory authorities for any use.
PF-06743649 has one completed clinical trial, NCT02151617, which evaluated multiple oral doses in healthy people. The study assessed safety, toleration, pharmacokinetics, and pharmacodynamics. It enrolled 40 participants in the United States and was a randomized, double-blind, controlled trial.
PF-06743649 is not FDA approved. It is an investigational drug that has completed a Phase 1 study in healthy volunteers. The drug is still in clinical development and has not been authorized for marketing or patient use.